Inventor · disambiguated record
Zhe Cai
Also filed as: CAI ZHE
8 granted patents·3 pending applications·3 citations·filing 2015–2025
74Inventor score
Files withCAI ZHE2CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD2FUJIAN AKEYLINK BIOTECHNOLOGY CO LTD2MEDSHINE DISCOVERY INC2ZHEJIANG YANGLI PHARMACEUTICAL TECH CO LTD2
Top patents by PatentIndex Score
11 records- 0180US12054482B2TLR8 agonistCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2019·Granted Aug 6, 2024·1 cites·11 claims
- 0274USD1101512SElectric lunch boxCAI ZHE·Filed 2025·Granted Nov 11, 2025·1 cites·1 claims
- 0360US9878982B2Pyridine derivatives and anti-mycobacterial use thereofCISEN PHARMACEUTICAL CO LTD·Filed 2015·Granted Jan 30, 2018·1 cites·13 claims
- 0459US11807647B2Crystal form of hepatitis B surface antigen inhibitor and application thereofFUJIAN AKEYLINK BIOTECHNOLOGY CO LTD·Filed 2020·Granted Nov 7, 2023·0 cites·14 claims
- 0554US12435101B2Isochroman compoundZHEJIANG YANGLI PHARMACEUTICAL TECH CO LTD·Filed 2021·Granted Oct 7, 2025·0 cites·14 claims
- 0652US2023183263A1Combination for treating hepatitis bFUJIAN AKEYLINK BIOTECHNOLOGY CO LTD·Filed 2021·Application pending·0 cites
- 0750US12071435B2TLR8 agonistCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2019·Granted Aug 27, 2024·0 cites·14 claims
- 0850US2025171474A1Crystal form of isochroman compoundZHEJIANG YANGLI PHARMACEUTICAL TECH CO LTD·Filed 2023·Application pending·0 cites
- 0950US2022281868A1Macrocyclic derivatives as factor xia inhibitorsMEDSHINE DISCOVERY INC·Filed 2020·Application pending·0 cites
- 1048US12457665B1Heating lunch boxCAI ZHE·Filed 2025·Granted Oct 28, 2025·0 cites·18 claims
- 1140US10508103B2Benzimidazole-linked indole compound acting as novel divalent IAP antagonistMEDSHINE DISCOVERY INC·Filed 2017·Granted Dec 17, 2019·0 cites·32 claims
Join the waitlist — get patent alerts
Get an alert when Zhe Cai files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →